Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Savara Inc., a clinical stage biopharmaceutical company, focuses on rare respiratory diseases. Its lead product candidate is molgramostim, an inhaled granulocyte-macrophage colony-stimulating factor, which is in Phase III development stage for the treatment of autoimmune pulmonary alveolar proteinosis. The company is headquartered in Austin, Texas.

Savara Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

LANGHORNE, PA.--(BUSINESS WIRE)--SAVARA INC. (NASDAQ: SVRA) (THE COMPANY), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON RARE RESPIRATORY DISEASES, REPORTED FINANCIAL RESULTS FOR THE SECOND QUARTER ENDING JUNE 30, 2025 AND PROVIDED A BUSINESS UPDATE. FOLLOWING A RECENT TYPE A MEETING WITH THE FDA, AND RECEIPT OF THE MEETING MINUTES, WE BELIEVE WE HAVE ALIGNED ON A PATH FORWARD FOR THE INFORMATION NEEDED TO RESUBMIT THE BLA WITH FUJIFILM AS OUR DRUG SUBSTANCE MANUFACTURER, SAID MATT PA.

SAVARA REPORTS SECOND QUARTER 2025 FINANCIAL RESULTS AND PROVIDES A BUSINESS UPDATE

LANGHORNE, PA.--(BUSINESS WIRE)--SAVARA INC. (NASDAQ: SVRA), A CLINICAL STAGE BIOPHARMACEUTICAL COMPANY FOCUSED ON RARE RESPIRATORY DISEASES, TODAY ANNOUNCED THE GRANT OF INDUCEMENT AWARDS TO TWO NEW EMPLOYEES. ON JULY 15, 2025, THE COMPENSATION COMMITTEE OF SAVARA'S BOARD OF DIRECTORS GRANTED THE INDUCEMENT AWARDS TO TWO NEW EMPLOYEES WHO RECENTLY JOINED THE COMPANY. THE INDUCEMENT AWARDS CONSIST OF OPTIONS TO PURCHASE AN AGGREGATE OF 20,000 SHARES OF THE COMPANY'S COMMON STOCK AND RESTRICTED.

SAVARA ANNOUNCES NEW EMPLOYMENT INDUCEMENT GRANT

NEW YORK , JULY 2, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF SAVARA INC.("SAVARA" OR THE "COMPANY") (NASDAQ: SVRA).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMS ON BEHALF OF INVESTORS OF SAVARA INC. - SVRA

NEW YORK , JUNE 27, 2025 /PRNEWSWIRE/ --POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF SAVARA INC.("SAVARA" OR THE "COMPANY") (NASDAQ: SVRA).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

NEW YORK , JUNE 22, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF SAVARA INC.("SAVARA" OR THE "COMPANY") (NASDAQ: SVRA).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

NEW YORK, JUNE 18, 2025 (GLOBE NEWSWIRE) -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF SAVARA INC. (SAVARA OR THE COMPANY) (NASDAQ: SVRA). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.7980.

INVESTOR ALERT: POMERANTZ LAW FIRM INVESTIGATES CLAIMSON BEHALF OF INVESTORS OF SAVARA INC. - SVRA

NEW YORK CITY, NY / ACCESS NEWSWIRE / JUNE 16, 2025 / POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF SAVARA INC.("SAVARA" OR THE "COMPANY") (NASDAQ:SVRA). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COM OR 646-581-9980, EXT.

NEW YORK CITY, NY / ACCESS NEWSWIRE / JUNE 13, 2025 / POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF SAVARA INC.("SAVARA" OR THE "COMPANY") (NASDAQ:SVRA). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COM OR 646-581-9980, EXT.

NEW YORK , JUNE 12, 2025 /PRNEWSWIRE/ -- POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF SAVARA INC.("SAVARA" OR THE "COMPANY") (NASDAQ: SVRA).SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COMOR 646-581-9980, EXT.

NEW YORK CITY, NY / ACCESS NEWSWIRE / JUNE 11, 2025 / POMERANTZ LLP IS INVESTIGATING CLAIMS ON BEHALF OF INVESTORS OF SAVARA INC.("SAVARA" OR THE "COMPANY") (NASDAQ:SVRA). SUCH INVESTORS ARE ADVISED TO CONTACT DANIELLE PEYTON AT NEWACTION@POMLAW.COM OR 646-581-9980, EXT.

Savara Inc.

SVRA

Price

Financials Overview

Financial Reports

No items found.

Press Releases

Savara Inc.

SVRA.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financials Overview

Financial Reports

No items found.

Press Releases

SVRA